Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 15;11:8279. doi: 10.1038/s41598-021-87441-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

EV-miRNA profiling of de novo NEPC shows distinct miRNA alterations from treatment-induced NEPC. (A) Representative NTA analyses of EVs isolated from primary adenocarcinomas (left) and de novo NEPC (right). (B) Western blot analyses for exosomal markers in EVs isolated from primary adenocarcinomas and de novo NEPC. Following transfer of gel, blots were cut according to molecular weights. Upper parts of blots were probed with Alix antibody and lower parts were probed with TSG101 antibody. Since CD63 and TSG101 fall in same size range, following stripping, blots were re-probed with CD63 antibody. (C) Heat map showing differentially expressed miRNAs in EVs from de novo NEPC patients and those with primary adenocarcinomas. Heat map was generated by using R studio software, Version 1.1.463 (https://www.npackd.org/p/rstudio/1.1.463). (D) Venn diagram showing miRNA altered significantly in de novo NEPC vs treatment induced NEPC.